Maxim Group analyst Jason McCarthy maintained a Buy rating on Femasys (FEMY – Research Report) yesterday and set a price target of $3.00.
Jason McCarthy has given his Buy rating due to a combination of factors surrounding Femasys’s innovative medical solutions and recent regulatory achievements. The company’s FemBloc treatment, a non-surgical permanent birth control method, has recently received EU approval, marking a significant milestone as the first global approval of this kind. This approval, along with the establishment of distribution partnerships in Spain, positions Femasys well in the European market.
Additionally, Femasys’s FemaSeed, an artificial insemination infertility treatment, has gained FDA 510(k) clearance and CE Mark approval, enhancing its credibility and market potential. The treatment offers a unique approach by delivering sperm directly to the fallopian tube, potentially increasing pregnancy success rates compared to traditional methods. The ongoing pivotal study for FemBloc, which has shown promising interim results, further supports the company’s growth prospects. These developments, combined with positive clinical data and strategic global partnerships, underpin McCarthy’s optimistic outlook on Femasys’s stock.
In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $15.00 price target.
FEMY’s price has also changed moderately for the past six months – from $1.120 to $1.540, which is a 37.50% increase.